Moreover, TCZ showed no risk of worsening diabetes status in terms of therapy intensification and switching to insulin in comparison to other bDMARDs.140 Consistent results were observed with SAR in a posthoc analysis, where SAR was associated with a greater reduction in glycosylated haemoglobin (HbA1c) than placebo or ADA in patients with diabetes.141. Here, INS is linked to diabetes mellitus.